Topical medication instillation techniques for glaucoma

Xu, Long; Wang, Xuemei; Wu, Meijing

doi:10.1002/14651858.cd010520.pub2

Cited by 3 publications

(3 citation statements)

References 56 publications

(93 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These eye drops reduce IOP by improving the outflow of AH through the trabecular drainage system or by reducing the volume of AH produced by the eye. However, the absorption of eye drop molecules into the bloodstream can result in side effects ( Xu et al, 2017 ). By way of explanation, beta-blockers are connected with cardiac arrhythmia, congestive heart failure, and airway obstruction ( Argulian et al, 2019 ), and carbonic anhydrase inhibitors may provoke thrombocytopenia ( Xu et al, 2017 ).…”

Section: Progress and Prospects For Research On Glaucoma Treatment Ta...mentioning

confidence: 99%

“…However, the absorption of eye drop molecules into the bloodstream can result in side effects ( Xu et al, 2017 ). By way of explanation, beta-blockers are connected with cardiac arrhythmia, congestive heart failure, and airway obstruction ( Argulian et al, 2019 ), and carbonic anhydrase inhibitors may provoke thrombocytopenia ( Xu et al, 2017 ). In some patients with advanced glaucoma, eye drops cannot lower the IOP to the required level and surgery or alternative treatment is needed.…”

Section: Progress and Prospects For Research On Glaucoma Treatment Ta...mentioning

confidence: 99%

See 1 more Smart Citation

Autophagy in glaucoma pathogenesis: Therapeutic potential and future perspectives

Gao

Zhang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Glaucoma is a common blinding eye disease characterized by progressive loss of retinal ganglion cells (RGCs) and their axons, progressive loss of visual field, and optic nerve atrophy. Autophagy plays a pivotal role in the pathophysiology of glaucoma and is closely related to its pathogenesis. Targeting autophagy and blocking the apoptosis of RGCs provides emerging guidance for the treatment of glaucoma. Here, we provide a systematic review of the mechanisms and targets of interventions related to autophagy in glaucoma and discuss the outlook of emerging ideas, techniques, and multidisciplinary combinations to provide a new basis for further research and the prevention of glaucomatous visual impairment.

show abstract

Section: Progress and Prospects For Research On Glaucoma Treatment Ta...mentioning

confidence: 99%

Section: Progress and Prospects For Research On Glaucoma Treatment Ta...mentioning

confidence: 99%

Autophagy in glaucoma pathogenesis: Therapeutic potential and future perspectives

Gao

Zhang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The topical agents for glaucoma therapy include beta-blockers, prostaglandin analogues, alpha agonists, and carbonic anhydrase inhibitors [ 40 ]. There are demerits associated with the conventional anti-glaucoma eye drops such as limited drug absorption, poor bioavailability, poor patient compliance, undesirable systemic side effects, and inaccurate dosing [ 40 , 41 ]. Several researchers have successfully developed in situ gelling systems to accomplish effective drug delivery for glaucoma therapy.…”

Section: Smart Ocular Delivery Using Stimuli-responsive In Situ Gel Platformmentioning

confidence: 99%

Potential of Stimuli-Responsive In Situ Gel System for Sustained Ocular Drug Delivery: Recent Progress and Contemporary Research

et al. 2021

View full text Add to dashboard Cite

Eyesight is one of the most well-deserved blessings, amid all the five senses in the human body. It captures the raw signals from the outside world to create detailed visual images, granting the ability to witness and gain knowledge about the world. Eyes are exposed directly to the external environment; they are susceptible to the vicissitudes of diseases. The World Health Organization has predicted that the number of individuals affected by eye diseases will rise enormously in the next decades. However, the physical barriers of the eyes and the problems associated with conventional ocular formulations are significant challenges in ophthalmic drug development. This has generated the demand for a sustained ocular drug delivery system, which serves to deliver effective drug concentration at a reduced frequency for consistent therapeutic effect and better patient treatment adherence. Recent advancement in pharmaceutical dosage design has demonstrated that a stimuli-responsive in situ gel system exhibits the favorable characteristics for providing sustained ocular drug delivery and enhanced ocular bioavailability. Stimuli-responsive in situ gels undergo a phase transition (solution–gelation) in response to the ocular environmental temperature, pH, and ions. These stimuli transform the formulation into a gel at the cul de sac to overcome the shortcomings of conventional eye drops, such as rapid nasolacrimal drainage and short contact time with the ocular surface This review highlights the recent successful research outcomes of stimuli-responsive in situ gelling systems in treating in vivo models with glaucoma and various ocular infections. Additionally, it also presents the mechanism, recent development, and safety considerations of stimuli-sensitive in situ gel as the potential sustained ocular delivery system for treating common eye disorders.

show abstract

Initial medication adherence in newly diagnosed glaucoma patients: three adherence measures

Menino¹,

Coelho²

2023

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To determine initial medication adherence in newly diagnosed glaucoma patients treated with anti-glaucoma drugs. METHODS: This retrospective and observational study included all patients diagnosed with glaucoma in the Primary Health Care units in Portugal during the years 2012 and 2013, which in consequence received a first prescription for anti-glaucoma drugs. Data was collected from electronic prescribing records of the primary care units and from pharmacy claims records. Initiation of glaucoma treatment and early discontinuation were measured, and the combination of (non)-initiation and early discontinuation accounted for initial medication (non)-adherence. RESULTS: A total of 3548 new glaucoma patients (40.1% male; 59.9% female) were included. The 1133 (31.9%) patients were initially classified as non-users, since there was no pharmacy claim found for their first prescription for glaucoma treatment. Additionally, 277 (11.5%) patients early discontinued their treatment, acquiring only their first prescription. Overall, the initial medication non-adherence rate was 39.7% since 1410 patients either didn’t initiate treatment or discontinued it early. CONCLUSION: This study, reveals a major opportunity to improve glaucoma treatment and its control, since a large proportion of patients fail to engage with their prescribed therapy, which implies that implementation of individual or group strategies that enable patients with glaucoma to correctly perform their treatment is still needed.

show abstract

Topical medication instillation techniques for glaucoma

Cited by 3 publications

References 56 publications

Autophagy in glaucoma pathogenesis: Therapeutic potential and future perspectives

Autophagy in glaucoma pathogenesis: Therapeutic potential and future perspectives

Potential of Stimuli-Responsive In Situ Gel System for Sustained Ocular Drug Delivery: Recent Progress and Contemporary Research

Initial medication adherence in newly diagnosed glaucoma patients: three adherence measures

Contact Info

Product

Resources

About